Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Receives Noncompliance Notice From Nasdaq Over Market Value of Shares

NEW YORK – Centogene said on Wednesday afternoon that it was notified by the Nasdaq on June 8 that it no longer complies with the minimum market value of publicly held shares (MVPHS) for continued listing on the Nasdaq Global Market.

Under the listing rule, a company must maintain a minimum MVPHS of $15 million, a requirement that Centogene has not met for 30 consecutive business days, from April 26 to June 7, triggering the notification.

The Rostock, Germany-based company now has until Dec. 5 to regain compliance by having its MVPHS close at $15 million or more for at least 10 consecutive business days.

Centogene received a separate noncompliance notice from Nasdaq in April because the closing bid price of its common shares had fallen below the minimum of $1.00 for 30 consecutive business days. It has until Oct. 23 to regain compliance with that requirement by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.

In early Thursday afternoon trading, Centogene's shares were down 4 percent at $.78.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.